Description

Retatrutide is a single molecule that activates three different receptors, GLP-1, GIP, and glucagon, currently in late-stage clinical trials for metabolic and weight-related research.

It’s getting attention because triple agonism appears to do things the dual-agonist class can’t, particularly around energy expenditure and body composition. The published Phase 2 data is what most of the conversation is built on.

Third-party verified, cold-chain shipped.

For research use only.